ABVX
ABIVAX Société Anonyme
Healthcare — Biotechnology
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Buy
1.5 / 5
11 analysts
$95.10
$-3.92 (-3.96%)
Target:
$150.73
(58.5%)
Price History
Sign in to add ABVX to a watchlist or set price alerts.
Fundamentals
| Market Cap | $10.69B |
| P/E Ratio (TTM) | - |
| Forward P/E | -40.99 |
| EPS (TTM) | $-5.25 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | Buy 1.5 |
| Analyst Target | $150.73 |
| Analysts | 11 |
| Next Earnings | Sep 21, 2026 AMC |
| Indexes | - |
Technical Indicators
| RSI (14) | 70.8 |
| Beta | -0.20 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | - |
| 52-Week Low | - |
| 50-Day Avg | - |
| 200-Day Avg | - |
| Avg Volume | - |
| Volume | - |
Performance Analysis
NEUTRALABVX presents a mixed picture with both positive and negative indicators.
-
RSI at 70.8 indicates overbought conditions — a pullback may be due.
+
Wall Street consensus is "Buy" from 11 analysts.
+
Average analyst target of $150.73 implies 58.5% upside.
Recent News
Loading news...
Last updated: Jul 01, 2026 11:46 UTC
Back to Screener Export Report